| 0 (0%) | 09-27 09:34 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 31.24 | 1-year : | 31.41 |
| Resists | First : | 26.75 | Second : | 26.89 |
| Pivot price | 26.68 | |||
| Supports | First : | 26.51 | Second : | 22.05 |
| MAs | MA(5) : | 26.68 | MA(20) : | 26.68 |
| MA(100) : | 26.68 | MA(250) : | 24.8  |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 43.5 | D(3) : | 43.5 |
| RSI | RSI(14): 77.7 | |||
| 52-week | High : | 26.89 | Low : | 11.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZGNX ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 26.96 - 27.1 | 27.1 - 27.2 |
| Low: | 26.14 - 26.32 | 26.32 - 26.47 |
| Close: | 26.43 - 26.7 | 26.7 - 26.92 |
Mon, 07 Mar 2022
UCB Completes Acquisition of Zogenix, Inc. - PR Newswire
Tue, 01 Feb 2022
How did UCB close its $1.9B deal to buy Zogenix and its key epilepsy drug? SEC filing reveals details - Fierce Pharma
Wed, 19 Jan 2022
UCB buys rare disease drugmaker Zogenix for up to $1.9B, bolstering its epilepsy position - Fierce Pharma
Wed, 19 Jan 2022
UCB offers $1.9B for Zogenix and its rare epilepsy drug Fintepla - BioWorld MedTech
Wed, 19 Jan 2022
Latham & Watkins Advises Zogenix in US$1.9 Billion Acquisition by UCB - Latham & Watkins LLP
Wed, 19 Jan 2022
UCB to Buy Epilepsy Drugmaker Zogenix for Up to $1.9 Billion - Bloomberg.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 56 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 107.2 (%) |
| Shares Short | 5,890 (K) |
| Shares Short P.Month | 6,540 (K) |
| EPS | -4.35 |
| EPS Est Next Qtrly | -0.93 |
| EPS Est This Year | -3.62 |
| EPS Est Next Year | -3.46 |
| Book Value (p.s.) | 4.01 |
| Profit Margin | 0 % |
| Operating Margin | -344 % |
| Return on Assets (ttm) | -23 % |
| Return on Equity (ttm) | -75.1 % |
| Qtrly Rev. Growth | 690.5 % |
| Gross Profit (p.s.) | -2.24 |
| Sales Per Share | 1.13 |
| EBITDA (p.s.) | -3.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -182 (M) |
| Levered Free Cash Flow | -97 (M) |
| PE Ratio | -6.14 |
| PEG Ratio | 0 |
| Price to Book value | 6.65 |
| Price to Sales | 23.49 |
| Price to Cash Flow | -8.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|